Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 193-201

  Degli Esposti, Luca ^a   Saragoni, Stefania ^a   Buda, Stefano ^a   Sturani, Alessandra ^b   Degli Esposti, Ezio ^a  

^a Economics and Outcomes Research   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Diabetes mellitus; Glycemic control; HbA1c; Health expenditure

Indexed keywords

ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA BASE; DIABETIC PATIENT; DISEASE REGISTRY; DYSLIPIDEMIA; FEMALE; GENDER; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY;

EID: 84877934780     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S41846     Document Type: Article

References (35)

1. International Diabetes Federation. Diabetes Atlas, 4th ed. Brussels, Belgium: International Diabetes Federation; 2009. Available from: http://www.diabetesatlas.org/content/diabetes. Accessed March 29, 2013.
2. Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol. 2005;5:143-148.
3. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
4. Stolar M.Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123 Suppl:S3-S11.
5. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc. 2000;40:475-485.
6. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed March 31, 2013.
7. Saydah S, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
8. National Diabetes Information Clearinghouse. National diabetes statistics, 2011. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed March 29, 2013.
9. Lauro R, Nicolucci A. Public Health and Health Policy. An informed health policy on chronic diseases Scientific Editor: Consorzio Mario Negri Sud; 2011.
10. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes-related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006;4:1.
11. Menzin J, Korn J, Cohen J, Lobo F. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16:264-275.
12. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.
13. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
14. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512-516.
15. Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21:238-245.
16. Di Bari M, Balzi D, Roberts AT, et al. Prognostic stratification of older persons based on simple administrative data: development and validation of the "Silver Code", to be used in emergency department triage. J Gerontol A Biol Sci Med. 2010;65:159-164.
17. Ministero del Lavoro, della Salute e delle Politiche Sociali. [Ministry of Labour, Health and Social Policies. Annual report on the hospitalization activity]. 2005. Available from: http://www.ministerosalute.it/programmazione/sdo/sezDocumenti.jsp?id=148&label=osp. Accessed April 24, 2009. Italian.
18. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
19. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006;12:466-471.
20. Informatore farmaceutico - Medicinali [Pharmaceutical Informer - Drugs]. 2012; Elsevier, Italy. Italian.
21. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9:197-204.
22. Khan L, Mincemoyer S, Gabbay RA. Diabetes registries: where we are and where are we headed? Diabetes Technol Ther. 2009;11: 255-262.
23. Brown JB, Nichols GA, Glauber HS. Case control study of 10 years of comprehensive diabetes care. West J Med. 2000;172:85-90.
24. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20:1396-1402.
25. ISTAT. [Health conditions and use of health services] 2008. Available from: http://www.ministerosalute.it/imgs/C_17_pubblicazioni_609_allegato.pdf. Italian.
26. Harris SB, Glazier RH, Tompkins JW, et al. Investigating concordance in diabetes diagnosis between primary care charts (electronic medical records) and health administrative data: retrospective cohort study. BMC Health Serv Res. 2010;10:347.
27. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: 405-412.
28. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-983.
29. [No authors listed]. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32 Suppl 1:S13-S61.
30. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London, UK: Royal College of Physicians; 2008.
31. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab. 2008;10 Suppl 1:8-15.
32. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001;24:51-55.
33. Shetty SS, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11: 559-564.
34. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for Type 2 diabetes: a retrospective cohort study of adults with employersponsored health insurance. Clin Ther. 2005;27:1064-1073.
35. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther. 2004;26:2066-2075.